Loading clinical trials...
Loading clinical trials...
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Conditions
Interventions
Hydroxychloroquine (HCQ)
Gemcitabine
+1 more
Locations
1
United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
December 1, 2011
Primary Completion Date
March 1, 2022
Completion Date
March 1, 2022
Last Updated
July 25, 2025
NCT04605913
NCT05808634
NCT05101356
NCT06225999
NCT04083235
NCT02065765
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions